WS-898
Customer Review
Based on 1 Customer Validation
WS-898 is a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively).
For research use only. We do not sell to patients.
- Purity: 98.51%
- CAS No.: 2891562-77-7
- Formula: C33H25N7OS
- Molecular Weight:567.66
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Size
Price
Stock
Quantity
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
You May Still Need
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Anti-Cancer Compound Library
HY-L025
-
Cancer Stem Cells Compound Library
HY-L135
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
Description
WS-898 is a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC50 = 5.0, 3.67, and 3.68 nM, respectively).
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
1.31 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM
|
[PMID: 34723530] |
| HEK293 | IC50 |
1.69 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/pcDNA3.1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1.93 +/- 0.06 nM
|
[PMID: 34723530] |
| HEK293 | IC50 |
3.68 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)
|
[PMID: 34723530] |
| HEK293 | IC50 |
9.21 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human HEK293/ABCB1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM)
|
[PMID: 34723530] |
| KB 3-1 | IC50 |
3.53 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)
|
[PMID: 34723530] |
| KB 3-1 | IC50 |
4.09 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB 3-1 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.54 +/- 1.59 nM)
|
[PMID: 34723530] |
| KB-C2 | IC50 |
15.94 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)
|
[PMID: 34723530] |
| KB-C2 | IC50 |
3.67 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human KB-C2 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)
|
[PMID: 34723530] |
| SW-620 | IC50 |
0.005 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)
|
[PMID: 34723530] |
| SW-620 | IC50 |
28.15 nM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)
|
[PMID: 34723530] |
| SW-620 | IC50 |
6.98 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 2 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)
|
[PMID: 34723530] |
| SW-620 | IC50 |
7.19 μM
Compound: 26
|
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 7.69 +/- 2.78 nM)
|
[PMID: 34723530] |
Chemical Information
-
CAS No. 2891562-77-7
-
Appearance Solid
-
Molecular Weight 567.66
-
Formula C33H25N7OS
-
Color Light yellow to yellow
-
SMILES
O=C(/C=C/C1=CC=C(C=CC=C2)C2=C1)C3=CC=C(NC4=CC(C)=NC5=NC(SCC6=NC7=C(C=CC=C7)N6)=NN54)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 25 mg/mL (44.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
View the Complete Stock Solution Preparation Table
Preparing Stock Solutions
View the Complete Stock Solution Preparation Table
Concentration
Solvent
Mass
1 mg
5 mg
10 mg
Concentration
Solvent
Mass
1 mM
1.7616 mL
8.8081 mL
17.6162 mL
5 mM
0.3523 mL
1.7616 mL
3.5232 mL
10 mM
0.1762 mL
0.8808 mL
1.7616 mL
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Molarity Calculator
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Dilution Calculator
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
Select Batch:
Purity:
99.98%
Assay:
99.98%
ee.:
99.98%
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7616 mL | 8.8081 mL | 17.6162 mL | 44.0404 mL |
| 5 mM | 0.3523 mL | 1.7616 mL | 3.5232 mL | 8.8081 mL | |
| 10 mM | 0.1762 mL | 0.8808 mL | 1.7616 mL | 4.4040 mL | |
| 15 mM | 0.1174 mL | 0.5872 mL | 1.1744 mL | 2.9360 mL | |
| 20 mM | 0.0881 mL | 0.4404 mL | 0.8808 mL | 2.2020 mL | |
| 25 mM | 0.0705 mL | 0.3523 mL | 0.7046 mL | 1.7616 mL | |
| 30 mM | 0.0587 mL | 0.2936 mL | 0.5872 mL | 1.4680 mL | |
| 40 mM | 0.0440 mL | 0.2202 mL | 0.4404 mL | 1.1010 mL |
Powered by Bioz